Live feed
·
INSIDERFilingvia Quantisnow
Kindred Biosciences, Inc. logo

Kindred Biosciences (KIN) executive Chin sold 40,000 shares for $367K at $9.18 under a 10b5-1 plan

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Richard Chin (executive at Kindred Biosciences, Inc., KIN) reported that they sold 40,000 shares for $367K at $9.18 on Jun 16, 2021. After these transactions the filing shows 1,934,271 shares held directly.

Reporting person
Chin Richard
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Jun 16, 2021Open-market sale (S)Common Stock1, 2-40,000$9.18$367K1,934,271 direct

Holdings before and after

  • Common Stock: 1,974,271 to 1,934,271 direct

Footnotes from the filing

  1. 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 22, 2020.
  2. 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.165 to $9.19, inclusive. The reporting person undertakes to provide to Kindred Biosciences, Inc., any security holder of Kindred Biosciences, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

Transaction codes in this filing

Open-market sale:
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

FAQ

What did Chin report in this KIN Form 4?

Richard Chin (executive at Kindred Biosciences, Inc., KIN) reported that they sold 40,000 shares for $367K at $9.18 on Jun 16, 2021. After these transactions the filing shows 1,934,271 shares held directly.

How many KIN shares does Chin hold after this filing?

The filing shows 1,934,271 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

Was this KIN insider sale made under a 10b5-1 plan?

The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.

What does transaction code S mean on an SEC Form 4?

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Historical context for KIN

Earlier insider filings at KIN

Quantisnow market dataNASDAQ
Kindred Biosciences, Inc. logo
KIN
Kindred Biosciences, Inc.
Market cap
30-day
Sector
Health Care
Industry
Major Pharmaceuticals
Listed since
2013
Get push alerts for KIN

Follow KIN and get a push notification the moment its next story breaks.

Full KIN profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KIN (Kindred Biosciences, Inc.) and more on Quantisnow.